See more : Aurea SA (AURE.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Sana Biotechnology, Inc. (SANA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sana Biotechnology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- E’Prime Aerospace Corporation (EPEO) Income Statement Analysis – Financial Results
- The BC Bud Corporation (BCBCF) Income Statement Analysis – Financial Results
- Eastcompeace Technology Co.,ltd (002017.SZ) Income Statement Analysis – Financial Results
- Rasa Corporation (3023.T) Income Statement Analysis – Financial Results
- CloudMD Software & Services Inc. (DOCRF) Income Statement Analysis – Financial Results
Sana Biotechnology, Inc. (SANA)
About Sana Biotechnology, Inc.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 30.87M | 27.73M | 17.91M | 10.17M | 3.92M | 1.00K |
| Gross Profit | -30.87M | -27.73M | -17.91M | -10.17M | -3.92M | -1.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 221.64M | 201.00M | 306.50M | 257.88M | 119.38M | 4.01M |
| General & Administrative | 73.30M | 71.56M | 50.41M | 28.27M | 21.78M | 8.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.21M |
| SG&A | 73.30M | 71.56M | 50.41M | 28.27M | 21.78M | 4.21M |
| Other Expenses | 0.00 | -674.00K | 305.00K | 97.00K | -29.00K | 0.00 |
| Operating Expenses | 294.94M | 272.56M | 356.91M | 286.15M | 141.15M | 8.22M |
| Cost & Expenses | 325.81M | 272.56M | 356.91M | 286.15M | 141.15M | 8.22M |
| Interest Income | 9.94M | 3.76M | 676.00K | 747.00K | 2.86M | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 30.87M | 27.73M | 17.91M | 10.17M | 3.92M | 1.00K |
| EBITDA | -252.39M | -256.94M | -356.91M | -287.03M | -138.90M | -13.25M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -326.90M | -272.56M | -356.91M | -286.15M | -141.15M | -8.22M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 43.65M | 3.09M | 981.00K | 844.00K | 2.83M | -5.03M |
| Income Before Tax | -283.26M | -269.48M | -355.93M | -285.31M | -138.33M | -13.25M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.09M | -11.75M | -6.67M | -7.55M | 0.00 |
| Net Income | -283.26M | -266.39M | -344.18M | -278.64M | -130.78M | -13.25M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.46 | -1.41 | -2.07 | -1.49 | -0.70 | -0.07 |
| EPS Diluted | -1.46 | -1.41 | -2.07 | -1.49 | -0.70 | -0.07 |
| Weighted Avg Shares Out | 194.54M | 188.34M | 166.43M | 187.51M | 187.34M | 187.34M |
| Weighted Avg Shares Out (Dil) | 194.54M | 188.34M | 166.43M | 187.51M | 187.34M | 187.34M |
Sana Biotechnology to build manufacturing in Seattle area, switching from California
Sana Biotechnology to Present at the BofA Securities 2022 Healthcare Conference
Sana Biotechnology to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting
Sana Biotechnology to Present at the 32nd Annual Oppenheimer Healthcare Conference
Sana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 American Association for Cancer Research Annual Meeting
Biotech IPOs Have Slowed to a Snail's Pace
Sana Biotechnology: Exciting Preclinical Science
3 Biotechs That Will Soar Regardless of COVID-19
Sana Biotechnology to Present at the 40th Annual J.P. Morgan Healthcare Conference
Sana Biotechnology to Present Pre-Clinical Data at 2021 American Society of Hematology Annual Meeting
Source: https://incomestatements.info
Category: Stock Reports